Oncology Pathology, Department of Pathology and Host-Defense, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
Int J Mol Sci. 2019 Aug 29;20(17):4224. doi: 10.3390/ijms20174224.
Approximately 30% of pancreatic cancer patients harbor targetable mutations. However, there has been no therapy targeting these molecules clinically. Nucleic acid medicines show high specificity and can target RNAs. Nucleic acid medicine is expected to be the next-generation treatment next to small molecules and antibodies. There are several kinds of nucleic acid drugs, including antisense oligonucleotides, small interfering RNAs, microRNAs, aptamers, decoys, and CpG oligodeoxynucleotides. In this review, we provide an update on current research of nucleic acid-based therapies. Despite the challenging obstacles, we hope that nucleic acid drugs will have a significant impact on the treatment of pancreatic cancer. The combination of genetic diagnosis using next generation sequencing and targeted therapy may provide effective precision medicine for pancreatic cancer patients.
约 30%的胰腺癌患者存在可靶向的突变。然而，目前临床上还没有针对这些分子的治疗方法。核酸药物具有高度特异性，可以靶向 RNA。核酸药物有望成为继小分子药物和抗体之后的下一代治疗方法。核酸药物有几种类型，包括反义寡核苷酸、小干扰 RNA、microRNA、适体、诱饵和 CpG 寡脱氧核苷酸。在这篇综述中，我们提供了基于核酸的治疗方法的最新研究进展。尽管面临着挑战，但我们希望核酸药物将对胰腺癌的治疗产生重大影响。使用下一代测序进行遗传诊断和靶向治疗的结合可能为胰腺癌患者提供有效的精准医学。
